In this article, European Pharmaceutical Review’s Hannah Balfour discusses how COVID-19 has impacted the pharma industry with regard to cancer clinical trial and treatment disruptions.
List view / Grid view
Head and Neck Cancer
Filter the results
Researchers have created targeted, modifiable nanoparticles which could be combined with pharmaceuticals as a form of drug delivery to treat cancer.
NICE has asked for more information on Keytruda (pembrolizumab) for untreated metastatic or unresectable recurrent squamous cell head and neck cancer due to uncertainty over clinical trial evidence.
The KEYNOTE-048 study examined the use of immunotherapy with pembrolizumab rather than the standard treatment using cetuximab for head and neck cancer...
8 March 2017 | By GBI Research
A substantial number of first-in-class products in the head and neck cancer pipeline will reach the market over the coming decade, which could potentially transform the clinical and commercial landscape, according to business intelligence firm GBI Research.
7 November 2016 | By Niamh Louise Marriott, Digital Content Producer
NICE was reconsidering cetuximab as part of its programme to appraise drugs that are currently available on the Cancer Drugs Fund...
10 October 2016 | By Niamh Louise Marriott, Digital Content Producer
An immunotherapy drug has been hailed as a ‘game changer’ after being found to greatly improve survival for patients with relapsed head and neck cancer...